Medhavi F, Tanner T, Richardson S, Lundy S, Omosun Y, Eko F
Biomedicines. 2025; 13(2).
PMID: 40002702
PMC: 11852492.
DOI: 10.3390/biomedicines13020288.
Dziadula J, Sabbaj S, Gupta K, Cutter G, Yu H, Brunham R
J Infect Dis. 2024; 230(3):569-577.
PMID: 38394609
PMC: 11420703.
DOI: 10.1093/infdis/jiae092.
Yu H, Geisler W, Dai C, Gupta K, Cutter G, Brunham R
Front Cell Infect Microbiol. 2024; 14:1342621.
PMID: 38371301
PMC: 10869445.
DOI: 10.3389/fcimb.2024.1342621.
Mayall J, Horvat J, Mangan N, Chevalier A, McCarthy H, Hampsey D
EMBO Mol Med. 2024; 16(2):267-293.
PMID: 38263527
PMC: 10897320.
DOI: 10.1038/s44321-023-00018-6.
Xu Y, Wang Y, Winner H, Yang H, He R, Wang J
Infect Immun. 2023; 92(1):e0042123.
PMID: 38047677
PMC: 10790816.
DOI: 10.1128/iai.00421-23.
Evaluation of three formulations based on Polymorphic membrane protein D in mice infected with .
Russi R, Del Balzo D, Reidel I, Alonso Bivou M, Flor N, Lujan A
Front Immunol. 2023; 14:1267684.
PMID: 38045697
PMC: 10690417.
DOI: 10.3389/fimmu.2023.1267684.
and Select Neighboring HLA Variants Predict Chlamydia Reinfection Risk.
Gupta K, Wiener H, Tiwari H, Geisler W
Int J Mol Sci. 2023; 24(21).
PMID: 37958786
PMC: 10647357.
DOI: 10.3390/ijms242115803.
Preclinical screen for protection efficacy of chlamydial antigens that are immunogenic in humans.
Lu C, Wang J, Zhong G
Infect Immun. 2023; 91(11):e0034923.
PMID: 37889004
PMC: 10652899.
DOI: 10.1128/iai.00349-23.
Identification of Key Genes Involved in Response to or spp. Infections in Human Cell Lines and in Mouse Organs.
Stepanenko E, Bondareva N, Sheremet A, Fedina E, Tikhomirov A, Gerasimova T
Int J Mol Sci. 2023; 24(17).
PMID: 37686095
PMC: 10487655.
DOI: 10.3390/ijms241713290.
Induction of Transmucosal Protection by Oral Vaccination with an Attenuated Chlamydia.
Wang Y, He R, Winner H, Gauduin M, Zhang N, He C
Infect Immun. 2023; 91(5):e0004323.
PMID: 37036335
PMC: 10187116.
DOI: 10.1128/iai.00043-23.
transmitting from the genital to gastrointestinal tract and inducing tubal disease: Double attack pattern.
.
Xu Y, Wang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(9):1275-1280.
PMID: 36411712
PMC: 10930326.
DOI: 10.11817/j.issn.1672-7347.2022.220023.
IFNγ and Antibody Synergize To Enhance Protective Immunity against Chlamydia Dissemination and Female Reproductive Tract Reinfections.
Gann J, Malaviarachchi P, Du W, Mercado M, Li L
Infect Immun. 2022; 90(12):e0032822.
PMID: 36374101
PMC: 9753678.
DOI: 10.1128/iai.00328-22.
Regulation of chlamydial colonization by IFNγ delivered via distinct cells.
Winner H, Friesenhahn A, Wang Y, Stanbury N, Wang J, He C
Trends Microbiol. 2022; 31(3):270-279.
PMID: 36175276
PMC: 9974551.
DOI: 10.1016/j.tim.2022.09.002.
IL-21/IL-21R Regulates the Neutrophil-Mediated Pathologic Immune Response during Chlamydial Respiratory Infection.
Zeng J, Xu Y, Tan L, Zha X, Yang S, Zhang H
Mediators Inflamm. 2022; 2022:4322092.
PMID: 35693111
PMC: 9177341.
DOI: 10.1155/2022/4322092.
The Role of IL-17 During Infections in the Female Reproductive Tract.
Bagri P, Anipindi V, Kaushic C
Front Immunol. 2022; 13:861444.
PMID: 35493460
PMC: 9046847.
DOI: 10.3389/fimmu.2022.861444.
Heterologous prime-boost vaccination based on Polymorphic protein D protects against intravaginal Chlamydia trachomatis infection in mice.
Russi R, Del Balzo D, Lujan A, Reidel I, Garcia M, Veaute C
Sci Rep. 2022; 12(1):6664.
PMID: 35459778
PMC: 9030682.
DOI: 10.1038/s41598-022-10633-x.
Interleukin-27 (IL-27) Promotes Chlamydial Infection in the Female Genital Tract.
Zhao Y, Huo Z, Zhou Z, Cervantes C, Chen J, Xu Z
Infect Immun. 2022; 90(4):e0065121.
PMID: 35258318
PMC: 9022568.
DOI: 10.1128/iai.00651-21.
Combining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures.
Johnson R, Asashima H, Mohanty S, Shaw A
J Infect Dis. 2022; 225(11):2033-2042.
PMID: 35172331
PMC: 9159333.
DOI: 10.1093/infdis/jiac051.
Chlamydia Deficient in Plasmid-Encoded Glycoprotein 3 (pGP3) as an Attenuated Live Oral Vaccine.
Zhou Z, Tian Q, Wang L, Zhong G
Infect Immun. 2022; 90(3):e0047221.
PMID: 35100010
PMC: 8929356.
DOI: 10.1128/IAI.00472-21.
Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Vaccine.
Richardson S, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme J
Front Immunol. 2021; 12:698737.
PMID: 34249004
PMC: 8264281.
DOI: 10.3389/fimmu.2021.698737.